Brokerage Firm Rating Update on ImmunoCellular Therapeutics Ltd. (IMUC)

ImmunoCellular Therapeutics Ltd. (IMUC) : 2 analysts are covering ImmunoCellular Therapeutics Ltd. (IMUC) and their average rating on the stock is 1, which is read as a Strong Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels.

ImmunoCellular Therapeutics Ltd. (IMUC) : Currently there are 2 street experts covering ImmunoCellular Therapeutics Ltd. (IMUC) stock. The most bullish and bearish price target for the stock is $2 and $1 respectively for the short term. The average price target of all the analysts comes to $1.35. The estimated standard deviation from the target is $0.92.


For the current week, the company shares have a recommendation consensus of Buy.

ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC): stock was range-bound between the intraday low of $0.1116 and the intraday high of $0.12 after having opened at $0.119 on Wednesdays session. The stock finally closed in the red at $0.119, a loss of -3.96%. The stock remained in the red for the whole trading day. The total traded volume was 4,524,852 shares. The stock failed to cross $0.12 in Wednesdays trading. The stocks closing price on Thursday was $0.1162.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Companys cancer immunotherapies targets cancer stem cells (CSCs). Its product candidates include ICT-107, which completed phase II testing, and also a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. ICT-107, the Companys lead product candidate, is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. In addition to ICT-107, the Company develops other therapeutic DC vaccines, including ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-121 specifically targets CD133, a CSC marker that is overexpressed in a variety of solid tumors, including ovarian, pancreatic, and breast cancers. Its product candidates also include stem cell therapies for cancer, which is in pre-clinical-stage.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.